WCG is the world's leading strategic partner to sponsors, CROs, institutions, and sites providing agile, knowledge based services that proactively optimize clinical development programs. For more information, visit www.wcgclinical.com.
WCG’s end-to-end patient recruitment solution connects patients to clinical trials, enhances site resources and capabilities, and improves study data quality and endpoints. On average, we are helping our clients achieve a 33% acceleration in their enrollment timelines.
The right sites can make all the difference. At WCG, we help clients to identify, select, and engage the highest performing investigators for their clinical research trials.
For 50 years, WIRB-Copernicus Group has stood as the gold standard of ethical and regulatory human research oversight, with more years of IRB and IBC experience and more deep, trusted relationships with sponsors, CROs, institutions, and investigators.
WCG offers the only global safety reporting solution and PV services that have been demonstrated to increase compliance and improve patient safety, while reducing cost and streamlining operations.
WCG
212 Carnegie Center
Princeton, NJ 08540
UNITED STATES
Phone: 609-945-0120
Contact: Lauren Ozmore
Clinical research is complicated. At WCG, we frequently get questions about the ethical conduct of research from clinical team members at biopharma companies and study sites. We know that for many of the questions we get, the person asking is not the only one struggling with that issue. Read the questions your peers are asking – and if you don’t see yours, submit one of your own.
Small and emerging biopharma companies are conducting almost 50% of the clinical trials in the United States today. Unlike “big pharma”, small companies are usually working with lean teams, limited resources, and minimal infrastructure. In this paper, we explore some of the unique challenges for clinical development teams, and solutions that can reduce the pressure on teams and timelines.
New research on how people make decisions about research participation, and new approaches to the question of payments and compensation to participants, bring a new perspective; are payments to participants actually too low? This paper explores this question, and whether we should, in fact, worry much less about restricting compensation for research participants.
Approximately 20% of cancer clinical trials will never be completed, because they fail to enroll enough participants to be able to answer the research question. Read this white paper to learn the impact that participant payments may play on clinical trial recruitment.
The WIRB-Copernicus Group® (WCG™) is pleased to announce the addition of several prominent executives to its Site Division and the expansion of its Global Research Network™ (GRN) of investigative sites. WCG is the leader in supporting clinical research sites in their critically important work of conducting clinical trials.
The WIRB-Copernicus Group®’s (WCG™) Clinical Services Division announces the acquisition of Analgesic Solutions, LLC, the global leader in the development of new pain medications and in the support of clinical trials in which pain is an indicator of an underlying condition.
WIRB-Copernicus Group® (WCG™) introduces WCG SiteReady™, a first-of-its-kind solution aimed at increasing the efficiency and profitability of clinical research for institutions and independent research sites. WCG’s newest offering helps researchers to optimize their performance, gain a competitive edge, and attract more opportunities for externally-funded clinical trials.
How can researchers identify participants’ overall level of suggestibility and then focus on the minimization of this characteristic to solve the issue of suggestibility in clinical trial?
Genetic testing is making it easier to identify patients for clinical trials. However, genetic testing in the context of clinical trials raises raise important ethical issues, including ones related to informed consent and disclosure of results. Genetic counselors can play a crucial role in helping sponsors address these operational and ethical issues, making trials more efficient, more patient-centered and, ultimately, more successful.
Overall, the landscape of patient recruitment and enrollment have become highly specialized and data-driven. They demand a specialized, data-driven approach that nurtures potential participants and delivers bottom-line results, quickly and within budget. Read how an Enrollment Assistant can reduce the site’s workload, accelerate enrollment and make the entire recruitment process more efficient.
The WIRB-Copernicus Group’s (WCG) Clinical Services Division has acquired the Velos eResearch business line. Velos is a leading provider of clinical trial management solutions (CTMS) that increase the productivity and efficiency of clinical research.
IN 2018 there were many changes, trends, regulations and priorities that shaped the direction of the clinical research and drug development fields. In this paper, WCG experts share what they anticipate in 2019, and what everyone should be prepared for as we approach another year of change.
Insights into the impact that the shutdown will have on the FDA and on the review of investigational products, including those reviews which were already in process at the time of the shutdown.
As you evaluate clinical trial enrollment acceleration strategies, be sure to understand the root causes of slow enrollment and the reasons why traditional acceleration programs do not work.
Study start-up delays have perplexed the best minds in the clinical trials industry for decades. Discover how advanced analytics and an intense focus on the four problem areas can help.
Patient engagement solutions to expedite study recruitment.
A breakdown of regulatory guidances and a clear picture of what the IRB needs to see.
Solutions to manage an overwhelming response to a media campaign.
Five characteristics to look for when finding the best-fit site for your study.
WCG™ (WIRB-Copernicus Group®) Clinical Services Division, the world’s leading provider of solutions that measurably improve the quality and efficiency of clinical research, recently announced the opening of the company’s new office in Tokyo, Japan.
